Simon signs on with Curve Therapeutics to strengthen Southampton biotech's leadership team

Southampton-based biotechnology Curve Therapeutics has announced the appointment of Simon Jones as Chief Financial Officer and Chief Operating Officer.

Simon brings more than 20 years’ experience in the biotech and pharma sector to the business, which is developing an intracellular screening platform addressing complex and challenging disease targets.

An accomplished C-suite executive, his skillset includes senior operational and commercial roles within the life-science sector, including significant venture fundraising and deal-making.

He joins from SpyBiotech, where he headed the Finance and Operations functions, during which time the Company successfully took its lead vaccine candidate into the clinic.

This followed almost a decade as CFO at Karus Therapeutics where he managed the financial operations as the Company secured a sizeable funding round from US and EU investors, as well as investment through the UK Government’s Future Fund Scheme.

Prior to this, Simon was CFO at various early-stage life sciences companies, including Eykona Technologies and Glide Pharmaceutical Technologies, which transitioned from development to commercialisation.

Simon Kerry, Chief Executive Officer of Curve Therapeutics, commented: “Simon brings extensive financial experience at the leadership level from multiple clinical stage biotech companies.

“His appointment comes at a pivotal time as we look to expand our team, advance our proprietary Microcycle® discovery platform, and progress our pipeline of potential first-in-class assets.”

Simon Jones, Chief Financial Officer and Chief Operating Officer of Curve Therapeutics, said: “Curve’s revolutionary Microcycle discovery platform and rich pipeline of assets means that it is a company primed to disrupt the drug discovery space.

“I am excited to be joining as the Company expands and transitions to become a clinical stage company.”